As part of the Top News in Medical Research at the Society of Physicians – Billrothhaus in Vienna, dermatologist Univ. Prof. Dr. Tamara Kopp of JUVENIS in Vienna reported on the efficacy of the specific blockade of Interleukin-23 in patients with Psoriasis (plaque psoriasis).

Psoriasis (also known as Schuppenflechte) is an inflammatory, non-contagious skin disease in which the body's own tissue is attacked by the immune system. Among other things, the immune system messenger Interleukin-23 is involved. By neutralizing it, the dermatologist Univ. Prof. Dr. Tamara Kopp and her team were able to significantly reduce symptoms of psoriasis.

Blockade of Interleukin-23 in Psoriasis (Schuppenflechte)

among others Univ. Prof. Dr. Tamara KoppThe dermatologist Univ. Prof. Dr. Tamara Kopp from the Schönheitszentrum JUVENIS in Vienna was a speaker as part of the Top News from Medical Research at the Society of Physicians – Billrothhaus in Vienna.

She reported on her study in which a total of 77 patients (with moderate to severe symptoms) received injections of varying doses of the antibody “Tildrakizumab” or a placebo. In patients treated with high doses, up to 100 percent of the skin was cleared of psoriasis symptoms.

Meanwhile, the researchers have completed a phase II of the study and are now in a clinical phase III study, which is the final stage before possible approval.

Further treatments for healthy skin in Vienna at JUVENIS

In addition to treatments for healthy skin in Vienna, JUVENIS offers additional services related to Health & preventive care, Radiance & posture as well as Outer beauty that make you outwardly radiant and enhance your well-being.

The lecture:Efficacy of the specific blockade of Interleukin-23 in patients with psoriasis
The study: “Clinical improvement in psoriasis with specific targeting of interleukin-23”, Nature (9.3.2015; doi: 10.1038/nature14175).